Bausch+Lomb Results Presentation Deck
Double Digit Total Revenue Growth with Strong Performance Across All Segments
2Q23 vs. 2Q22
10% Reported Revenue Growth
12% CC³ Revenue Growth¹
Pharmaceuticals
19%
Surgical
19%
$1,035M
2Q23
Revenue
BAUSCH + LOMB
Vision
Care
62%
$179M 2023 Adj. EBITDA¹
-$25M FX headwinds
Vision Care²
2Q23 REPORTED REVENUE
$646M
2Q23 CONSTANT CURRENCY
REVENUE GROWTH¹
+12%
Growth momentum in Lumify,
Daily SiHy, Eye Vitamins, Artelac
System upgrade at U.S. distribution
facility impacted lens business
Surgical
2Q23 REPORTED REVENUE
$195M
2Q23 CONSTANT CURRENCY
REVENUE GROWTH¹
+7%
Continued strength in demand,
growth in Premium IOL portfolio
Focused on providing
consistent supply of products
Pharmaceuticals 2,4
2Q23 REPORTED REVENUE
$194M
2Q23 CONSTANT CURRENCY
REVENUE GROWTH¹
+16%
Growth across all major
markets including China
Strong execution in
U.S. Gx portfolio
1. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported
results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The
net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
3. Constant currency.
4. Effective as of the second quarter of 2023, the company changed the name of the segment from "Ophthalmic Pharmaceuticals" to "Pharmaceuticals". Aside from the change in name, there were no other changes to the segment itself as a result.
6View entire presentation